Previous studies have demonstrated that HDAC inhibitors are potent particularly in AML with AML1/ETO and PML-RARα fusion proteins since they can recruit HDAC-containing complexes and provide targets for HDAC inhibitors [28]. Here, RUNX1 is linked to acute myeloid leukemia.